|
|
|
Volumn 6, Issue 1 SUPPL. 2, 2010, Pages 13-14
|
|
Biologic therapies for Crohn's disease: Update from the 2009 ACG Meeting: Commentary
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BIOLOGICAL FACTOR;
CERTOLIZUMAB PEGOL;
INFLIXIMAB;
NATALIZUMAB;
PLACEBO;
TUMOR NECROSIS FACTOR INHIBITOR;
ANASTOMOSIS;
BRAIN INFECTION;
CLINICAL ASSESSMENT;
CLINICAL TRIAL;
COHORT ANALYSIS;
CROHN DISEASE;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG DOSE ESCALATION;
DRUG DOSE INCREASE;
DRUG EFFICACY;
DRUG INFUSION;
DRUG MEGADOSE;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
ENTERITIS;
GASTROINTESTINAL ENDOSCOPY;
HUMAN;
INFECTION;
MULTIPLE SCLEROSIS;
NOTE;
POSTOPERATIVE PERIOD;
PREGNANCY;
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
PROSPECTIVE STUDY;
QUALITY OF LIFE;
RECURRENT DISEASE;
REMISSION;
TREATMENT DURATION;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
|
|
EID: 77950845950
PISSN: 15547914
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
